Copyright © 1999 by the European Society of Cardiology.
Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial
a Thoraxcenter, University Hospital Dijkzigt, Rotterdam, The Netherlands
b Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
c Hôpital Bichat, Paris, France
d UZ Gasthuisberg, Leuven, Belgium
e Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium
f Charing Cross Hospital, London, U.K.
g Cardialysis, Rotterdam, The Netherlands
revised April 13, 1999; accepted April 14, 1999
Abstract
Background The CAPTURE study (c 7E3 A nti P lateletT herapy in U nstable Re fractory angina) was designed to assess outcome in patients with refractory angina undergoing angioplasty, receiving either abciximab or placebo.
Methods One thousand two hundred and sixty-five patients with refractory unstable angina, defined as recurrent myocardial ischaemia despite medical treatment including heparin and nitrates were enrolled. After angiography, patients received an infusion of abciximab or placebo over 18–24h preceding angioplasty, continuing until 1h after the procedure. In 1197 patients undergoing angioplasty the angiographic committee centrally reviewed the baseline as well as the procedural angiograms. Coronary flow and lesion characteristics were assessed in the baseline angiogram as well as before intervention. Angiographic outcome, reason for failure as well as complications were assessed after angioplasty.
Results At 30 days follow-up, patients receiving abciximab (n=595) compared with placebo (n=602) had a 30% reduction in the composite primary end-point death, myocardial infarction or urgent (re)intervention: 10·8% vs 15·4% (P=0·017). Baseline demographics were identical in the angiogram available group compared with the total study group. At 30 days, the non-angiogram available patients showed a higher incidence of events compared to those in whom the angiogram was reviewed: 19·4 vs 13·1% (P=ns). Lesion characteristics and coronary flow were not different at baseline between the placebo and abciximab groups. A primary end-point was reached in 9·6% of both placebo and abciximab patients with type A or B1lesions, in 17·0% vs 12·0% with type B2lesions, and in 19·1% vs 11·5% with type >B2or C lesions. Sixty-one percent of placebo and abciximab patients had TIMI 3 flow at baseline angiography. Pre-angioplasty TIMI 3 flow was observed in 69% and 72% respectively. The thrombus was resolved between the angiograms in 22% and 43% respectively, in the placebo and abciximab groups (P=0·033). Angiographic success of the procedure was achieved in 88% and 94% in the placebo and abciximab patients, respectively (P<0·001). Stents were implanted in the ischaemia-related artery in 56 and 60 patients, respectively. However, failure of the stent procedure was more frequent in the placebo group than in the abciximab group, nine vs no patients (P=0·003).
Conclusion More frequent thrombus resolution was observed and a higher angiographic success rate was achieved in patients treated with abciximab before and during angioplasty compared with placebo. Patients with complex lesions as the underlying pathology reached fewer end-points if treated with abciximab before and during angioplasty.
Key Words: Angina, platelet aggregation inhibitors, angiography, angioplasty
f1 Correspondence: Dr M. van den Brand, Thoraxcenter BD 412, University Hospital Dijkzigt Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Cavallini and F. Chirillo Non-ST-elevation acute coronary syndromes management: a fresh look at glycoprotein IIb/IIIa inhibitors Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K10 - K14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wenaweser, C. Rey, F. R. Eberli, M. Togni, D. Tuller, S. Locher, A. Remondino, C. Seiler, O. M. Hess, B. Meier, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome Eur. Heart J., June 2, 2005; 26(12): 1180 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-J. Neumann, A. Kastrati, G. Pogatsa-Murray, J. Mehilli, H. Bollwein, H.-P. Bestehorn, C. Schmitt, M. Seyfarth, J. Dirschinger, and A. Schomig Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes: A Randomized Controlled Trial JAMA, September 24, 2003; 290(12): 1593 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Cannon Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 43S - 48S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Boden "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 113S - 122S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Gibson, J. A. de Lemos, S. A. Murphy, S. J. Marble, C. H. McCabe, C. P. Cannon, E. M. Antman, and E. Braunwald Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction : A TIMI 14 Substudy Circulation, May 29, 2001; 103(21): 2550 - 2554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colombo Different benefits, different risks, equal cost Eur. Heart J., November 1, 1999; 20(21): 1531 - 1532. [PDF]
|
|